DJIA 17,002.12 19.53 0.12%
NASDAQ 4,461.40 16.49 0.37%
S&P 500 1,979.71 0.80 0.04%
market minute promo

Nektar Therapeutics (NASDAQ: NKTR)



company name or ticker

Nektar Therapeutics Is The Seattle Genetics Of San Francisco But It Could Be More

Nektar Presents Positive Data from Phase 1 Study of Etirinotecan Pegol in Combination with 5-Flourou

Nektar Presents Positive Data from Phase 1 Study of Etirinotecan Pegol in Combination with 5-Flourouracil/Leucovorin at 2014 Gastrointestinal Cancers Symposium

Pipeline Progress at Nektar - Analyst Blog

Piper Jaffray Has Four Biotech Stocks to Buy With Huge Potential

Nektar Therapeutics' CEO Presents at 32nd Annual JPMorgan Healthcare Conference (Transcript)

Cadence Pharmaceuticals Inc. (CADX) Soars: Stock Adds 13.0% in Session - Tale of the Tape

Time to Buy Nektar Therapeutics (NKTR) After Recent Moving Average Crossover? - Tale of the Tape

Etirinotecan Pegol Passes Interim Efficacy Analysis for BEACON Pivotal Phase 3 Clinical Study in Pat

Etirinotecan Pegol Passes Interim Efficacy Analysis for BEACON Pivotal Phase 3 Clinical Study in Patients with Metastatic Breast Cancer

Flamel Technologies (FLML) in Focus: Stock Jumps 8.6% - Tale of the Tape

Flamel Technologies (FLML) in Focus: Stock Jumps 8.6% - Tale of the Tape

MannKind's Pit Stop on the Road to Approval

MannKind's inhaled insulin Afrezza will face an advisory committee meeting in April.
See More Articles...